Patient characteristics and auxological data at baseline and after 1 year of growth hormone treatment for patients naive to growth hormone treatment at study entry and with baseline and 1-year height measurements available, by primary diagnostic category*
| Characteristic | Diagnostic category; mean (95% CI)† | ||||
|---|---|---|---|---|---|
| Organic growth hormone deficiency | Idiopathic growth hormone deficiency | Turner syndrome | Idiopathic short stature | Small for gestational age | |
| Canada | n = 89 | n = 57 | n = 44 | n = 25 | n = 5 |
| Baseline | |||||
| Male sex, no. (%) | 54 (61) | 38 (67) | – | 21 (84) | 4 (80) |
| Age, yr | 8.9 (7.8 to 10.0) | 11.3 (10.2 to 12.4) | 9.6 (8.5 to 10.6) | 12.9 (11.8 to 14.0) | 6.3 (3.7 to 9.0) |
| Height SDS | −1.87 (−2.13 to −1.60) | −2.58 (−2.91 to −2.25) | −2.76 (−2.97 to −2.55) | −2.57 (−2.96 to −2.18) | −4.02 (−5.40 to −2.65) |
| Height velocity, cm/yr | 5.17 (4.12 to 6.22) | 4.22 (3.39 to 5.04) | 4.96 (4.24 to 5.67) | 4.58 (3.78 to 5.37) | 6.32 (3.15 to 9.49) |
| Height velocity SDS | −1.65 (−2.05 to −1.24) | −1.55 (−2.04 to −1.05) | −1.01 (−1.54 to −0.47) | −0.61 (−1.58 to 0.35) | 0.31 (−4.70 to 5.32) |
| Target height SDS | 0.25 (0.03 to 0.47) | −0.37 (−0.64 to −0.10) | 0.18 (−0.04 to 0.40) | −0.44 (−0.72 to −0.15) | −0.62 (−1.26 to 0.03) |
| Target height SDS deficit‡ | −2.19 (−2.54 to −1.84) | −2.22 (−2.62 to −1.83) | −2.92 (−3.18 to −2.66) | −2.13 (−2.55 to −1.72) | −3.41 (−5.16 to −1.65) |
| Stimulated peak growth hormone level, μg/L | 4.3 (2.4 to 6.1) | 4.4 (3.6 to 5.3) | NA 25.0 (17.2 to 32.8) | NA | |
| Growth hormone dosage, mg/kg per wk | 0.18 (0.17 to 0.19) | 0.18 (0.17 to 0.19) | 0.29 (0.28 to 0.30) | 0.22 (0.19 to 0.25) | 0.22 (0.15 to 0.29) |
| Year 1 | |||||
| Height SDS | −1.30 (−1.54 to −1.05) | −1.97 (−2.29 to −1.65) | −2.28 (−2.54 to −2.03) | −2.24 (−2.64 to −1.83) | −3.45 (−4.75 to −2.15) |
| Height velocity, cm/yr | 9.30 (8.28 to 10.33) | 8.79 (8.14 to 9.44) | 7.84 (7.28 to 8.40) | 7.31 (6.33 to 8.28) | 7.24 (5.59 to 8.90) |
| Height velocity SDS | 1.72 (1.31 to 2.13) | 2.20 (1.58 to 2.81) | 2.54 (1.54 to 3.53) | 1.47 (0.76 to 2.17) | 1.49 (−0.12 to 3.10) |
| Height SDS gain | 0.59 (0.43 to 0.76) | 0.60 (0.46 to 0.73) | 0.50 (0.38 to 0.61) | 0.33 (0.21 to 0.45) | 0.57 (0.14 to 1.00) |
| Target height SDS deficit‡ | −1.60 (−1.93 to −1.27) | −1.61 (−1.99 to −1.24) | −2.44 (−2.72 to −2.16) | −1.80 (−2.23 to −1.36) | −2.83 (−4.46 to −1.20) |
| Growth hormone dosage, mg/kg per wk | 0.19 (0.18 to 0.20) | 0.19 (0.18 to 0.20) | 0.30 (0.29 to 0.31) | 0.24 (0.21 to 0.27) | 0.27 (0.21 to 0.33) |
| All countries combined (including Canada) | n = 1210 | n = 5974 | n = 886 | n = 1353 | n = 756 |
| Baseline | |||||
| Male sex, no. (%) | 766 (63.3) | 3988 (66.8) | – | 967 (71.5) | 405 (53.6) |
| Age, yr | 8.8 (8.5 to 9.1) | 10.3 (10.2 to 10.4) | 9.2 (9.0 to 9.4) | 11.5 (11.3 to 11.6) | 8.6 (8.3 to 8.8) |
| Height SDS | −2.42 (−2.50 to −2.34) | −2.39 (−2.41 to −2.37) | −2.56 (−2.62 to −2.50) | −2.36 (−2.40 to −2.32) | −2.62 (−2.68 to −2.56) |
| Height velocity, cm/yr | 4.54 (4.32 to 4.75) | 4.70 (4.64 to 4.77) | 4.86 (4.66 to 5.06) | 4.81 (4.65 to 4.96) | 5.22 (5.02 to 5.41) |
| Height velocity SDS | −1.56 (−1.70 to −1.42) | −0.99 (−1.04 to −0.93) | −1.11 (−1.26 to −0.96) | −0.72 (−0.84 to −0.60) | −0.84 (−0.99 to −0.69) |
| Target height SDS | −0.06 (−0.11 to 0.00) | −0.55 (−0.57 to −0.53) | 0.07 (0.01 to 0.13) | −0.54 (−0.59 to −0.50) | −0.64 (−0.70 to −0.58) |
| Target height SDS deficit‡ | −2.42 (−2.50 to −2.33) | −1.84 (−1.86 to −1.81) | −2.62 (−2.69 to −2.55) | −1.82 (−1.87 to −1.76) | −1.98 (−2.07 to −1.90) |
| Stimulated peak growth hormone level, μg/L | 4.5 (4.1 to 4.8) | 8.2 (8.0 to 8.4) | N/A | 16.9 (16.3 to 17.4) | 14.1 (13.1 to 15.1) |
| Growth hormone dosage, mg/kg per wk | 0.22 (0.21 to 0.22) | 0.23 (0.23 to 0.24) | 0.31 (0.31 to 0.32) | 0.32 (0.32 to 0.33) | 0.27 (0.27 to 0.28) |
| Year 1 | |||||
| Height SDS | −1.65 (−1.72 to −1.58) | −1.85 (−1.87 to −1.83) | −2.10 (−2.16 to −2.04) | −1.87 (−1.91 to −1.82) | −2.05 (−2.11 to −2.00) |
| Height velocity, cm/yr | 9.76 (9.54 to 9.98) | 8.79 (8.73 to 8.85) | 7.83 (7.70 to 7.97) | 8.63 (8.51 to 8.76) | 8.52 (8.37 to 8.68) |
| Height velocity SDS | 3.21 (3.02 to 3.40) | 2.48 (2.42 to 2.54) | 2.26 (2.07 to 2.45) | 2.38 (2.26 to 2.50) | 2.34 (2.19 to 2.49) |
| Height SDS gain | 0.78 (0.74 to 0.82) | 0.56 (0.55 to 0.57) | 0.48 (0.46 to 0.51) | 0.52 (0.50 to 0.54) | 0.58 (0.55 to 0.61) |
| Target height SDS deficit‡ | −1.63 (−1.70 to −1.55) | −1.29 (−1.32 to −1.27) | −2.16 (−2.23 to −2.09) | −1.31 (−1.37 to −1.26) | −1.41 (−1.49 to −1.33) |
| Growth hormone dosage, mg/kg per wk | 0.23 (0.22 to 0.23) | 0.25 (0.25 to 0.25) | 0.32 (0.32 to 0.33) | 0.35 (0.35 to 0.36) | 0.29 (0.29 to 0.30) |
Note: CI = confidence interval, NA = data available for less than 60% of patients, SDS = standard deviation score.
↵* Patient numbers are for those with height SDS at baseline and 1 year, but not all patients had all other information.
↵† Except where noted otherwise.
↵‡ Height SDS minus target height SDS.